Calypso Biotech SA

Swiss Biotech Association

Member

Calypso Biotech, a preclinical-stage spin-off from Merck Serono, develops therapeutic antibodies for severe diseases of the gastro-intestinal tract.

Cooperation possibilities

Calypso Biotech is willing to enter into collaboration(s) to support the pharmacological validation of CALY-001 and CALY-002 in translational medicine experiments, develop biomarkers, and support IND-enabling studies, including manufacturing.

http://www.calypsobiotech.com
+41 22 552 33 07
Alain Vicari

Location

Chemin des Aulx 14, 1228 Plan-les-Ouates, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2013
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Sintetica SA

Sintetica is a pharmaceutical company delivering injectable medicines to patients worldwide, through innovative science and excellence in development, production and marketing. The multicultural high-performing organization is built to support both the national growth and the global expansion.
Mendrisio

Member

Labatec Pharma SA

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.
Meyrin

Member

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member